Filing Analysis
Unicycive Therapeutics, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2026, and provided a general business update.
📋 Key Facts
- Reporting date: August 12, 2026
- Period covered: Second Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
- Company is classified as an emerging growth company.
Unicycive Therapeutics reported its preliminary cash position for the second quarter ending June 30, 2026. The company maintains a significant cash balance of approximately $61.4 million.
🚩 Red Flags
- Results are preliminary and unaudited, which carries inherent risk of future restatement upon formal audit.
📋 Key Facts
- Ending cash balance as of June 30, 2026: approximately $61.4 million.
- Reported under Item 8.01 (Other Events).
- Preliminary results for Q2 2026 have not been audited or reviewed by independent accountants.
Unicycive Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 19, 2026. The meeting resulted in the election of three directors and the ratification of Grassi & Co. CPAs, P.C. as the independent auditor for fiscal year 2026.
📋 Key Facts
- Annual Meeting held on June 19, 2026.
- Quorum represented by 14,964,159 shares of common stock.
- Three directors elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare-Mitra.
- Grassi & Co. CPAs, P.C. ratified as independent auditor for fiscal year ending Dec 31, 2026.
Unicycive Therapeutics entered into Amendment No. 2 to its existing At-The-Market (ATM) Sales Agreement with Guggenheim Securities on June 5, 2026. This amendment increases the total aggregate offering price of common stock available for sale through the ATM facility from $100 million to $150 million.
🚩 Red Flags
- Significant potential dilution: Increasing the ATM capacity by $50 million (a 50% increase over the previous limit) can lead to substantial dilution of existing shareholders, especially for a micro-cap company.
📋 Key Facts
- Amendment No. 2 to the Sales Agreement was executed on June 5, 2026.
- The total aggregate offering price for the ATM Offering increased from $100,000,000 to $150,000,000.
- The company filed a Shelf Registration Statement on Form S-3 on June 5, 2026, to facilitate the sale of an additional $50,000,000 in common stock.
- Guggenheim Securities, LLC continues to serve as the sales agent.
Unicycive Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing includes a press release providing a business update and financial performance details for the period.
📋 Key Facts
- Reported Q1 2026 financial results on May 12, 2026
- The financial period covered ended March 31, 2026
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- Included a press release as Exhibit 99.1
On April 6, 2026, Gaurav Aggarwal resigned from the Board of Directors of Unicycive Therapeutics, Inc. The company reported that the departure was not due to any disagreements regarding operations, policies, or practices.
📋 Key Facts
- Director Gaurav Aggarwal resigned effective April 6, 2026.
- The resignation was not the result of any disagreement with the Company, management, or the Board.
- The company is listed on the Nasdaq Capital Market under the symbol UNCY.
Unicycive Therapeutics, Inc. reported its full-year 2025 financial results and provided a business update on March 30, 2026. The filing is a routine disclosure of annual performance via a furnished press release.
📋 Key Facts
- Announced financial results for the full year ended December 31, 2025
- Press release issued and furnished on March 30, 2026
- Included a business update alongside the financial results
- The information is furnished under Item 2.02 and not considered 'filed' for liability purposes
Unicycive Therapeutics, Inc. has amended its existing 'at the market' (ATM) sales agreement with Guggenheim Securities, LLC to significantly increase its capacity for equity issuance.
🚩 Red Flags
- Significant increase in potential dilution: The company has doubled its capacity to issue new common stock via the ATM offering.
- Continuous need for capital: The expansion of an ATM facility often indicates a high burn rate or a strategic need for immediate liquidity typical of clinical-stage biotech firms.
📋 Key Facts
- The Company entered into Amendment No. 1 to its Sales Agreement on November 14, 2025.
- The amendment increases the aggregate offering price of shares that can be sold through the ATM Offering from $50,000,000 to $100,000,000.
- The original Sales Agreement was dated November 13, 2024, and is part of a Shelf Registration Statement on Form S-3 effective as of November 20, 2024.
Unicycive Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025, and provided a general business update.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Three months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.
Unicycive Therapeutics issued an 8-K providing preliminary, unaudited financial results for the quarter ended September 30, 2025, and an update regarding FDA resubmission timelines for Oxylanthanum Carbonate.
🚩 Red Flags
- Financial data is preliminary and unaudited; subject to change pending completion of condensed consolidated financial statements.
📋 Key Facts
- Preliminary cash and cash equivalents estimated at approximately $42 million as of September 30, 2025.
- The company is preparing to resubmit its New Drug Application (NDA) for Oxylanthanum Carbonate following a Complete Response Letter received on June 30, 2025.
- Full financial results will be provided in the upcoming Form 10-Q.
Unicycive Therapeutics, Inc. announced on August 15, 2025, that it is facing a securities class action lawsuit in the Northern District of California. The suit alleges violations of federal securities laws regarding public statements made about its new drug application for oxylanthanum carbonate.
🚩 Red Flags
- Securities class action litigation involving officers of the company.
- Potential legal costs and management distraction associated with federal securities law allegations.
📋 Key Facts
- Lawsuit filed in United States District Court for the Northern District of California.
- The action targets the Company and certain officers.
- Allegations concern public statements related to the New Drug Application (NDA) for oxylanthanum carbonate phosphate binder.
- Oxylanthanum carbonate is intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis.
- Company states it believes the claims are meritless and intends to defend against them.
Unicycive Therapeutics, Inc. announced the sale of 3,549,846 shares of common stock under a previously established sales agreement with Guggenheim Securities, LLC. The transaction resulted in net proceeds of approximately $16.3 million.
🚩 Red Flags
- Equity dilution: The issuance of over 3.5 million shares will dilute existing shareholders.
📋 Key Facts
- Sold 3,549,846 shares of common stock.
- Average sale price per share: $4.56.
- Total net proceeds to the Company: approximately $16.3 million.
- The sale was executed pursuant to a sales agreement dated November 13, 2024, with Guggenheim Securities, LLC.
Unicycive Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided a general business update.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Three months ended June 30, 2025
- The filing includes the announcement of financial results and a business update via press release (Exhibit 99.1).
Unicycive Therapeutics, Inc. announced on July 8, 2025, that it has regained compliance with the Nasdaq minimum share price requirement under Rule 5550(a)(2). This follows a period of non-compliance regarding its stock price.
🚩 Red Flags
- Historical non-compliance with minimum share price requirements (Rule 5550(a)(2)) indicates past volatility or significant downward pressure on stock price.
📋 Key Facts
- Company regained compliance with Nasdaq Stock Market continued listing standard for minimum share price.
- Compliance achieved under Rule 5550(a)(2) of the Nasdaq Listing Qualifications.
- The announcement was made via a press release dated July 8, 2025.
Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for oxylanthanum carbonate (OLC). This represents a significant regulatory setback for the company's lead candidate intended to treat hyperphosphatemia in chronic kidney disease patients.
🚩 Red Flags
- FDA Complete Response Letter (CRL) indicates the current application is not approved in its present form.
- Regulatory setback directly impacts the company's primary value driver/pipeline asset.
- Preliminary cash position of $20.7M may be subject to change and requires monitoring relative to upcoming R&D burn rate.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) for the NDA of oxylanthanum carbonate (OLC).
- Target indication: Hyperphosphatemia in patients with chronic kidney disease on dialysis.
- Preliminary cash and cash equivalents as of June 30, 2025, are estimated at approximately $20.7 million.
- Financial results for the quarter ended June 30, 2025, are not yet finalized.
Unicycive Therapeutics, Inc. has implemented a 1-for-10 reverse stock split to consolidate its outstanding common shares. The split became effective on June 18, 2025, and trading began on a split-adjusted basis on June 20, 2025.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance or mitigate low share price perception).
- Significant reduction in the number of outstanding shares.
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date of the reverse split: June 18, 2025, at 4:01 p.m. ET.
- Trading on Nasdaq resumed on a split-adjusted basis on June 20, 2025.
- Issued and outstanding shares reduced from approximately 126,409,281 to approximately 12,768,239.
- The company's CUSIP number has changed to 90466Y202.
Unicycive Therapeutics, Inc. issued an 8-K to announce a press release regarding a regulatory update for its New Drug Application (NDA) for oxylanthanum carbonate.
📋 Key Facts
- Company announced an update on its NDA for oxylanthanum carbonate.
- The drug is intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
- Filed under Item 8.01 (Other Events) on June 10, 2025.
Unicycive Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2025, where stockholders approved a proposal for a reverse stock split and ratified the company's independent auditor.
🚩 Red Flags
- Approval of a Reverse Stock Split: Typically used by micro-cap companies to boost share price to meet exchange listing requirements (e.g., Nasdaq minimum bid price), often signaling potential delisting risk or significant dilution/capital structure distress.
📋 Key Facts
- Annual Meeting held on June 9, 2025, with approximately 69.70% of total voting power represented.
- Stockholders approved Proposal 3: A Reverse Stock Split (78,097,588 votes in favor).
- Four directors were elected to the Board: Dr. Gaurav Aggarwal, Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare-Mitra.
- Stockholders ratified Grassi & Co CPAs, P.C. as the independent registered public accounting firm for fiscal year 2025.
Unicycive Therapeutics, Inc. announced a change to the time of its 2025 Annual Meeting of Stockholders. The meeting remains scheduled for June 9, 2025, but will now commence at 7:00 a.m. PDT.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is still set for June 9, 2025.
- The meeting location remains unchanged at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
- The time has been updated to 7:00 a.m. Pacific Daylight Time.
- The record date for stockholders was April 30, 2025.
Unicycive Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025, and provided a general business update.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.
Unicycive Therapeutics entered into an exchange agreement with accredited investors to restructure its preferred stock and warrants. This involved the elimination of several existing preferred series (A-1 through A-5) in favor of a new 'Series A Prime' structure and significant downward adjustments to warrant coverage.
🚩 Red Flags
- Significant dilution/restructuring of existing equity classes (Elimination of Series A-1 through A-5).
- Complex restructuring of warrants and preferred stock often indicates a need to manage debt or prevent imminent liquidation/default.
- The massive reduction in warrant share counts suggests previous terms were highly dilutive, necessitating this correction.
📋 Key Facts
- Entered into an Exchange Agreement on March 13, 2024, with accredited investors.
- Investors surrendered 43,649,000 shares of Series A-2 Preferred Stock in exchange for 21,388.01 shares of new 'Series A-2 Prime Preferred' stock.
- Eliminated Series A-1, A-2, A-3, A-4, and A-5 Preferred Stock via Certificates of Elimination filed with the Delaware Secretary of State.
- Amended Tranche A, B, and C warrants to significantly reduce the number of shares issuable upon exercise (e.g., Tranche A reduced from 47.8M to 25.8M shares).
- Revised warrant exercise prices to $1,000 per share for Series A-3, A-4, and A-5 Preferred Stock.
- New conversion prices for the new preferred series are set at $0.49, $0.54, $0.59, and $0.74 respectively.
Unicycive Therapeutics, Inc. filed an 8-K to announce its full-year financial results for the period ending December 31, 2024, and provided a general business update.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Full year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.
Unicycive Therapeutics, Inc. has failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement within the initial 180-day grace period. The company has been granted a second 180-day extension, providing until July 7, 2025, to rectify the deficiency.
🚩 Red Flags
- Failure to meet Nasdaq minimum bid price requirement ($1.00).
- Expiration of the initial compliance period indicates ongoing stock price weakness.
- Risk of delisting if compliance is not achieved by July 7, 2025.
📋 Key Facts
- The Company's common stock closed below $1.00 for 30 consecutive business days as of July 9, 2024.
- Nasdaq granted an initial 180-day compliance period ending January 6, 2025.
- As of January 6, 2025, the Company failed to regain compliance.
- Nasdaq notified the Company on January 7, 2025, of a second 180-day extension until July 7, 2025.
Unicycive Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ending September 30, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Three months ended September 30, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1)
- Company is classified as an emerging growth company
Unicycive Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). The FDA has set a PDUFA target action date of June 28, 2025.
📋 Key Facts
- FDA acceptance of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC).
- PDUFA target action date is set for June 28, 2025.
- Filing includes a press release as Exhibit 99.1.
Unicycive Therapeutics has regained compliance with Nasdaq's minimum market value requirement after a period of non-compliance. The company successfully maintained a market value of $35,000,000 or greater for 10 consecutive business days ending September 23, 2024.
🚩 Red Flags
- Previous non-compliance with Nasdaq listing rules indicates historical volatility in market capitalization.
📋 Key Facts
- The Company was previously in violation of Nasdaq Listing Rule 5550(b)(2) regarding minimum market value requirements.
- Nasdaq confirmed the company's market value was $35,000,000 or greater for the period from September 10 to September 23, 2024.
- On September 24, 2024, Nasdaq officially notified the Company that it has regained compliance with the minimum market value requirement.
Unicycive Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results and a business update for the three months ended June 30, 2024.
📋 Key Facts
- Report date: August 14, 2024
- Reporting period: Three months ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- Company is an emerging growth company.
Unicycive Therapeutics received two separate notices from Nasdaq regarding non-compliance with listing requirements. The company failed to meet the $1.00 minimum bid price requirement and the $35 million Minimum Market Value of Listed Securities (MVLS) requirement.
🚩 Red Flags
- Dual delisting notices (Bid Price and Market Value) indicate significant downward pressure on stock price and market cap.
- Risk of delisting from Nasdaq Capital Market if compliance is not achieved by early January 2025.
- Potential for mandatory reverse stock split to regain bid price compliance.
📋 Key Facts
- Received notice on July 9, 2024, regarding failure to maintain a $1.00 minimum bid price for 30 consecutive business days.
- Received notice on July 11, 2024, regarding failure to meet the $35 million Minimum Market Value of Listed Securities (MVLS) requirement.
- The company has until January 6, 2025, to regain compliance with the minimum bid price requirement.
- The company has until January 7, 2025, to regain compliance with the MVLS requirement.
- Compliance requires meeting the respective thresholds for at least 10 consecutive business days during the grace periods.
Unicycive Therapeutics received a notice from Nasdaq stating it is non-compliant with the $1.00 minimum bid price requirement after closing below that threshold for 30 consecutive business days. The company has until January 6, 2025, to regain compliance through a 180-day grace period.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days, indicating significant downward momentum/market distress.
📋 Key Facts
- Received written notice from Nasdaq on July 9, 2024.
- Non-compliance due to violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price.
- The company has a 180-day period to regain compliance, ending January 6, 2025.
- To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days during the grace period.
Unicycive Therapeutics entered into a First Amendment to its Manufacturing and Supply Agreement with Shilpa Medicare, Ltd. on June 26, 2024. The amendment is designed to scale manufacturing capacity for oxylanthanum carbonate (OLC) in anticipation of increased market demand.
🚩 Red Flags
- The company is providing direct funding to a third-party manufacturer for a new production line, which represents an upfront capital outlay/risk.
📋 Key Facts
- Effective Date: June 26, 2024.
- Counterparty: Shilpa Medicare, Ltd., an Indian corporation.
- Purpose: To address anticipated increased manufacturing demand for OLC.
- Commitments: Company made a binding purchase order for tablets to be delivered by June 30, 2025; additional orders scheduled for delivery between Dec 31, 2025, and June 30, 2026.
- Funding: The Company agreed to provide certain funding to Shilpa for a new manufacturing line.
- Term: Agreement lasts until the 8th anniversary of FDA approval of OLC's NDA, with subsequent 4-year renewal periods.
Unicycive Therapeutics, Inc. filed an 8-K to report a stockholder-approved increase in authorized common stock. The company doubled its authorized share count from 200 million to 400 million shares.
🚩 Red Flags
- Significant increase in authorized shares can lead to future dilution if used for equity financing or compensation.
📋 Key Facts
- Stockholders approved the increase on June 20, 2024.
- Authorized shares increased from 200,000,000 to 400,000,000.
- Certificate of Amendment filed with the Delaware Secretary of State on June 21, 2024.
Unicycive Therapeutics announced positive results from its UNI-OLC-201 pivotal clinical trial for Oxylanthanum Carbonate (OLC), meeting both primary and secondary endpoints. The company also provided a corporate presentation detailing these clinical findings.
📋 Key Facts
- Positive results reported from the UNI-OLC-201 pivotal clinical trial on June 25, 2024.
- The trial achieved both its Primary and Secondary Endpoints.
- The drug under investigation is Oxylanthanum Carbonate (OLC).
- Company issued a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) regarding the results.
Unicycive Therapeutics, Inc. held its Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the election of four directors and the approval of several key shareholder proposals, including an auditor ratification and a Nasdaq 20% issuance proposal.
🚩 Red Flags
- Approval of an 'Authorized Share Increase Proposal' often indicates potential future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Quorum represented approximately 78% of total voting power (35,912,732 votes).
- All four director nominees (Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. Gaurav Aggarwal, and Dr. Saraswati Kenkare-Mitra) were elected.
- Stockholders ratified Grassi & Co. CPAs, P.C. as independent auditors for fiscal year 2024.
- The 'Nasdaq 20% Issuance Proposal' was approved by stockholders.
- An 'Authorized Share Increase Proposal' was approved by stockholders.
- The second amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved.
Unicycive Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024, and provided a general business update.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: May 13, 2024.
- The filing includes an earnings press release as Exhibit 99.1.
Unicycive Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided a general business update.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes results of operations and financial conditions under Item 2.02.
- A press release containing the full update is attached as Exhibit 99.1.
Unicycive Therapeutics entered into a $50 million private placement agreement to issue 50,000 shares of Series B-1 Convertible Preferred Stock. The offering includes significant dividend escalators and conversion terms that may lead to substantial dilution for existing shareholders.
🚩 Red Flags
- High dividend escalator (from 8% to 14%) if conversion approval is not obtained
- Potential for significant dilution via the conversion of Series B Preferred Stock into Common Stock
- Requirement to file an S-3 registration statement for resale of shares, creating potential overhang
- Liquidation preference includes accrued dividends and potentially higher payouts in a change of control
📋 Key Facts
- Aggregate purchase price: $50 million
- Security type: Series B-1 Convertible Preferred Stock (with associated Series B-2)
- Initial conversion price: $1.00 per share
- Annual dividend rate: 8% compounded annually, increasing to 14% if stockholder approval for conversion is not obtained
- Placement agents: Leerink Partners and Piper Sandler & Co. (7.0% cash fee)
- Expected closing date: On or about March 18, 2024
- Use of proceeds: Clinical development pipeline advancement and general working capital
Unicycive Therapeutics entered into an exchange agreement to restructure its preferred stock and warrants, effectively eliminating several previous series of preferred stock (Series A-1 through A-5) in favor of a new 'Series A-2 Prime' and amended versions of existing warrants. This restructuring significantly reduces the number of shares issuable under existing warrants while adjusting conversion prices for various preferred series.
🚩 Red Flags
- Complex capital restructuring involving the elimination of multiple preferred stock series.
- Significant reduction in the number of shares issuable via warrants, indicating a defensive move to mitigate potential massive dilution.
- The complexity and scale of the exchange suggest significant pressure from existing investors/creditors regarding the company's capital structure.
📋 Key Facts
- Entered into an Exchange Agreement on March 13, 2024, with accredited investors.
- Investors surrendered 43,649,000 shares of Series A-2 Preferred Stock in exchange for 21,388.01 shares of new 'Series A-2 Prime Preferred' stock.
- Filed Certificates of Elimination for Series A-1, A-2, A-3, A-4, and A-5 Preferred Stock effective March 14, 2024.
- Amended Tranche A, B, and C warrants to reduce the aggregate number of shares issuable upon exercise (e.g., Tranche A reduced from 47,852,430 to 25,840,312 shares).
- Revised warrant exercise prices to $1,000 per share for Series A-3, A-4, and A-5.
- Conversion prices for new preferred series set at $0.49 (Series A-2 Prime), $0.54 (Series A-3), $0.59 (Series A-4), and $0.74 (Series A-5).
Unicycive Therapeutics, Inc. announced that it has regained compliance with Nasdaq's Minimum Market Value and Minimum Bid Price requirements. This resolves the delisting notices previously issued by Nasdaq on September 19, 2023.
🚩 Red Flags
- Historical delisting risk: The company was previously under threat of delisting due to low market capitalization and share price.
📋 Key Facts
- On February 21, 2024, Nasdaq notified the Company it has regained compliance with the Minimum Market Value Requirement (Nasdaq Listing Rule 5550(b)(2)).
- The Company also regained compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- The matters regarding these specific non-compliance issues are now considered closed by Nasdaq.